CXCL11 is a C-X-C chemokine that functions primarily as a T-cell chemoattractant through binding to CXCR3 and CXCR7 receptors 1. It selectively recruits interleukin-activated T cells and induces calcium release in these cells 2, while lacking the ELR motif characteristic of neutrophil-recruiting chemokines 2. CXCL11 expression is strongly induced by interferon-gamma, particularly in Th1-mediated immune responses 2. In disease contexts, CXCL11 plays significant roles across multiple pathologies. In CNS diseases including multiple sclerosis and neurodegenerative conditions, CXCL11 correlates with T-cell tissue infiltration and neuroinflammation 2. Elevated CXCL11 precedes ulcerative colitis diagnosis by years, suggesting utility as a predictive biomarker 3. During chr4 HIV-1 infection, CXCL11 associates with T-cell dysregulation and impaired immune recovery 4. In cancer, CXCL11 exhibits context-dependent functions. Therapy-induced senescent endothelial cells secrete CXCL11, which promotes breast cancer cell proliferation and invasion through ERK pathway activation 5. CXCL11 shows complex, cell-type-dependent interactions with CXCL12 affecting tumor progression 6. Generally, CXCL11 inhibits angiogenesis and suppresses M2 macrophage polarization while facilitating immune cell migration 7, suggesting potential as a therapeutic target, though its pleiotrophic effects necessitate cell-type and context-specific strategies 1.